SGS to operate Ph I inpatient clinical trials at Budapest hospital

By Melissa Fassbender contact

- Last updated on GMT

SGS to operate Ph I inpatient clinical trials at Budapest hospital

Related tags: Pharmacology, Hospital

SGS has signed a partnership agreement under which it will operate a dedicated clinical pharmacology unit for conducting Ph I inpatient clinical trials in Budapest, Hungary.

The agreement with the Medical Center of Defense Forces Hospital further expands the company’s embedded hospital clinical pharmacology network.

The clinical and bioanalytical contract solutions provider also has facilities in Antwerp and Mechelen, Belgium.

"Eastern ​Europe, and Hungary specifically, is a great place to reach naive patients and having this unit creates a win-win partnership between local experts and the hospital​," Florent Hediard at SGS Life Science told Outsourcing-Pharma.com.

"This ensures full control and oversight of clinical trials to guarantee the study trial quality, compliance with international rules, scientific exchanges between SGS and the hospital staff, and access for local patients to the latest treatments​."

As part of the agreement, the hospital dedicated some of its facilities and SGS invested in the equipment and local staff to maintain and manage the unit.

The new patient unit is located in a secured wing close to the intensive care unit and will feature five hospitalization beds. It is also equipped with an examination room, a sample preparation area, a sample storage area/locker, and restrooms.

A permanent, on-site SGS team will conduct the early phase trials in collaboration with hospital physicians, trial experts, and investigators.

"There is an ​on going clinical trial within this hospital for an oncology treatment​," Hediard explained. "SGS will use this new phase I unit to coordinate other 'sister' units within other hospitals with a local/close direct support​."

ISO 13485:2016

SGS has also announced​ that it has been granted accreditation for ISO 13485:2016, following a transition assessment done by United Kingdom Accreditation Service (UKAS).

According to the International Organization for Standardization (ISO), ISO 13485:2016 “specifies requirements for a quality management system where an organization needs to demonstrate its ability to provide medical devices and related services that consistently meet customer and applicable regulatory requirements​.”

(Feature image: iStock/megaflopp)

Related topics: Clinical Development, Phase I-II

Related news

Show more

Related products

show more

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us

Products

View more

Webinars